Table 1

Baseline characteristics of the eligible patients

CharacteristicsChlorambucil (n = 100)Fludarabine (n = 93)
Age (y) 70 (65-78) 71 (65-78) 
Age group, %   
    65-69 y 47 45 
    70-74 y 31 33 
    75-79 y 22 22 
Binet stage, %   
    A 16 13 
    B 44 51 
    C 40 36 
Rai stage, %   
    0: low risk 
    I or II: intermediate risk 52 55 
    III or IV: high risk 43 40 
Male sex, % 63 66 
Median time from initial diagnosis to study entry (mo) 11 (0-110) 17 (0-92) 
ECOG performance status, %   
    0 42 46 
    1 49 52 
    2 
Concomitant disease, %   
    None 33 35 
    1 35 32 
    2 or more 32 33 
    Thymidine kinase (U/L) 20 (3-108) 18 (4-71) 
β2 microglobulin (mg/L) 4 (2-8) 4 (2-7) 
Patients with del(17p), n (%) 5 (6) 5 (7) 
Patients with del(11q), n (%) 8 (10) 14 (19) 
Patients with 12q+, n (%) 17 (20) 16 (25) 
Patients with unmutated IgVH (%) 27 (59) 28 (67) 
CharacteristicsChlorambucil (n = 100)Fludarabine (n = 93)
Age (y) 70 (65-78) 71 (65-78) 
Age group, %   
    65-69 y 47 45 
    70-74 y 31 33 
    75-79 y 22 22 
Binet stage, %   
    A 16 13 
    B 44 51 
    C 40 36 
Rai stage, %   
    0: low risk 
    I or II: intermediate risk 52 55 
    III or IV: high risk 43 40 
Male sex, % 63 66 
Median time from initial diagnosis to study entry (mo) 11 (0-110) 17 (0-92) 
ECOG performance status, %   
    0 42 46 
    1 49 52 
    2 
Concomitant disease, %   
    None 33 35 
    1 35 32 
    2 or more 32 33 
    Thymidine kinase (U/L) 20 (3-108) 18 (4-71) 
β2 microglobulin (mg/L) 4 (2-8) 4 (2-7) 
Patients with del(17p), n (%) 5 (6) 5 (7) 
Patients with del(11q), n (%) 8 (10) 14 (19) 
Patients with 12q+, n (%) 17 (20) 16 (25) 
Patients with unmutated IgVH (%) 27 (59) 28 (67) 

Median values are given for continuous variables (5th to 95th percentiles); percentages are given for categorical values.

ECOG indicates Eastern Cooperative Oncology Group.

Close Modal

or Create an Account

Close Modal
Close Modal